State of Alaska Department of Revenue Increases Stock Holdings in Omnicell, Inc. $OMCL

State of Alaska Department of Revenue lifted its position in Omnicell, Inc. (NASDAQ:OMCL) by 8.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,906 shares of the company’s stock after purchasing an additional 2,242 shares during the quarter. State of Alaska Department of Revenue owned about 0.06% of Omnicell worth $819,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of OMCL. Pacer Advisors Inc. purchased a new stake in shares of Omnicell in the first quarter valued at about $10,542,000. Nuveen LLC purchased a new stake in shares of Omnicell in the first quarter valued at about $6,218,000. Wellington Management Group LLP grew its holdings in shares of Omnicell by 52.6% in the first quarter. Wellington Management Group LLP now owns 496,680 shares of the company’s stock valued at $17,364,000 after purchasing an additional 171,116 shares during the period. Strs Ohio purchased a new stake in shares of Omnicell in the first quarter valued at about $5,635,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock valued at $58,745,000 after purchasing an additional 154,038 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on OMCL. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, July 21st. Piper Sandler decreased their target price on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research report on Saturday, September 27th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $46.71.

Insiders Place Their Bets

In related news, EVP Corey J. Manley sold 3,880 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the sale, the executive vice president owned 110,653 shares of the company’s stock, valued at $3,679,212.25. This trade represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.52% of the stock is currently owned by company insiders.

Omnicell Trading Down 1.4%

NASDAQ OMCL opened at $30.52 on Tuesday. The firm has a 50 day simple moving average of $31.54 and a 200-day simple moving average of $30.52. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of 61.04, a PEG ratio of 6.76 and a beta of 0.88.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same quarter last year, the firm posted $0.51 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.